Stock IPH INNATE PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

News Innate Pharma

Equities

IPH

FR0010331421

Real-time Euronext Paris
Other stock markets
 06:30:12 2024-04-16 am EDT 		5-day change 1st Jan Change
2.195 EUR -2.88% Intraday chart for Innate Pharma -4.57% -16.22%
01:35pm Sanofi: progress in hematology trial CF
08:44am Innate Pharma: progress in hematology trial CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sanofi: progress in hematology trial
CF
Innate Pharma: progress in hematology trial
CF
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
BU
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
BU
Innate Pharma: IPH45 data presented at AACR
CF
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
BU
Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
CI
Innate Pharma Announces Its Participation in Upcoming Investor Conference
BU
INNATE PHARMA FILES ITS 2023 UNIVERSAL REGISTRATION DOCUMENT AND 2023 ANNUAL REPORT ON FORM 20-F
AQ
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
BU
Transcript : Innate Pharma S.A., 2023 Earnings Call, Mar 21, 2024
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
BU
Innate Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Innate Pharma Announces Its Participation to Upcoming Investor Conference
BU
Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results
BU
INNATE PHARMA SA - FIRST PATIENT DOSED IN PHASE 1/2 STUDY OF IPH6501 IN RELAPSED, REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA
AQ
Innate Pharma initiates lymphoma trial
CF
Innate Pharma: abstract on IPH45 at the AACR congress
CF
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
BU
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPH Stock
  4. News Innate Pharma